Category : Diet

At the occasion of the "New therapies in coeliac disease" conference hosted by Columbia University in New-York on March 20, 2014, Dr. Elena Verdú, our expert in Nutrition, is sharing with us the last trends in research in the field of Coeliac Disease (CeD), introducing the idea of a role of probiotics in the treatment of CeD. Presence of intestinal dysbiosis…

Elena Verdú
Dr. Verdu’s research has focused on the pathophysiology of inflammatory and functional gastrointestinal disorders. She undertook clinical research training at the University of Lausanne, Switzerland, where she studied the interaction between chronic infection with Helicobacter pylori and gastritis in humans and the possible therapeutic role of probiotic bacteria. Her PhD studies in the Institute of Microbiology and Gnotobiology at the Czech Academy of Science and University of Lausanne focused on the effect of bacterial antigens in animal models of inflammatory bowel disease. As a post-doctoral fellow at McMaster University she gained experience with animal models of gut functional diseases and investigated the mechanisms of action of probiotic bacteria. As a member of the Farncombe Family Digestive Health Research Institute at McMaster University, Dr. Verdu investigates host-microbial and dietary interactions in the context of celiac disease, irritable bowel syndrome and inflammatory bowel disease. She has been honored with the New Investigator Award (Canadian Celiac Association), the New Investigator Award (Functional Gut-Brain Research Group, USA) and the Campbell Research Award in celiac disease (Canadian Celiac Association). The American Gastroenterology Association and the Canadian Association of Gastroenterology have awarded her the “Master’s in Gastroenterology Award” for basic science and “Young Investigator’s Award”, respectively. She is Associate Professor at the Division of Gastroenterology, Dep. of Medicine at McMaster University and currently directs the Axenic Gnotobiotic Unit at McMaster.

At the occasion of the "New therapies in coeliac disease" conference hosted by Columbia University in New-York on March 20, 2014, Dr. Elena Verdú, our expert in Nutrition, is sharing with us the last trends in research in the field of Coeliac Disease (CeD), introducing the idea of a role of probiotics in the treatment of CeD. Presence of intestinal dysbiosis…

Elena Verdú
Dr. Verdu’s research has focused on the pathophysiology of inflammatory and functional gastrointestinal disorders. She undertook clinical research training at the University of Lausanne, Switzerland, where she studied the interaction between chronic infection with Helicobacter pylori and gastritis in humans and the possible therapeutic role of probiotic bacteria. Her PhD studies in the Institute of Microbiology and Gnotobiology at the Czech Academy of Science and University of Lausanne focused on the effect of bacterial antigens in animal models of inflammatory bowel disease. As a post-doctoral fellow at McMaster University she gained experience with animal models of gut functional diseases and investigated the mechanisms of action of probiotic bacteria. As a member of the Farncombe Family Digestive Health Research Institute at McMaster University, Dr. Verdu investigates host-microbial and dietary interactions in the context of celiac disease, irritable bowel syndrome and inflammatory bowel disease. She has been honored with the New Investigator Award (Canadian Celiac Association), the New Investigator Award (Functional Gut-Brain Research Group, USA) and the Campbell Research Award in celiac disease (Canadian Celiac Association). The American Gastroenterology Association and the Canadian Association of Gastroenterology have awarded her the “Master’s in Gastroenterology Award” for basic science and “Young Investigator’s Award”, respectively. She is Associate Professor at the Division of Gastroenterology, Dep. of Medicine at McMaster University and currently directs the Axenic Gnotobiotic Unit at McMaster.

Dr Elena Verdú's lab seeks to understand the complex pathophysiology of gastrointestinal disease, with a focus on microbiota-diet interactions, to identify novel therapeutic targets for these disorders.     1/ What strikes you most in the evolution of research on gut microbiota and why? One interesting aspect relates to the way we have approached the study of the microbiota. We…

GMFH Editing Team
GMFH Editing Team

Dr Elena Verdú's lab seeks to understand the complex pathophysiology of gastrointestinal disease, with a focus on microbiota-diet interactions, to identify novel therapeutic targets for these disorders.     1/ What strikes you most in the evolution of research on gut microbiota and why? One interesting aspect relates to the way we have approached the study of the microbiota. We…

GMFH Editing Team
GMFH Editing Team

Filipe De Vadder is a molecular biologist in Gilles Mithieux group and published recently an important article in Cell journal which illustrate how gut microbiota fermentation product could impact neural communication. He accepted for GMFH to give us some highlights. 1) What is the context of this study? Dietary fiber has long been known for its beneficial effects on health,…

GMFH Editing Team
GMFH Editing Team

Filipe De Vadder is a molecular biologist in Gilles Mithieux group and published recently an important article in Cell journal which illustrate how gut microbiota fermentation product could impact neural communication. He accepted for GMFH to give us some highlights. 1) What is the context of this study? Dietary fiber has long been known for its beneficial effects on health,…

GMFH Editing Team
GMFH Editing Team

Some individuals seem to be more susceptible to develop obesity or are more resistant to weight loss during dietary restriction. Emerging evidence suggest that few bacterial genera (i.e., Bifidobacterium, Lactobacillus, Faecalibacterium and Akkermansia) are inversely associated with obesity, metabolic inflammation and related metabolic disorders in both human and rodent studies. However so far, a common integrative factor is still being…

Patrice D. Cani
Professor Patrice D. Cani is researcher from the Belgian Fund for Scientific Research (FRS-FNRS), group leader in the Metabolism and Nutrition research group at the Louvain Drug Research Institute (LDRI) from the Université catholique de Louvain (UCL), Brussels, Belgium, and WELBIO (Walloon Excellence in Lifesciences and BIOtechnology) investigator. He is currently member of several international associations, he is member of the Alumni College from the Royal Belgian Academy of Sciences, and he has been elected in the board of directors of the LDRI (UCL). Patrice D. Cani has a M.Sc. in Nutrition and another M.Sc. in health Sciences, he is registered dietitian and PhD in Biomedical Sciences. His main research interests are the investigation of the role of the gut microbiota in the development of metabolic disorders, such as obesity, type 2 diabetes and low grade inflammation. More specifically, he is investigating the interactions between the gut microbiota, the host and specific biological systems such as the endocannabinoid system and the innate immune system in the context of obesity, type 2 diabetes and metabolic inflammation. Prof Cani is author and co-author of more than 110 scientific research papers published in peer-reviewed international journals, conferences and book chapters.

Some individuals seem to be more susceptible to develop obesity or are more resistant to weight loss during dietary restriction. Emerging evidence suggest that few bacterial genera (i.e., Bifidobacterium, Lactobacillus, Faecalibacterium and Akkermansia) are inversely associated with obesity, metabolic inflammation and related metabolic disorders in both human and rodent studies. However so far, a common integrative factor is still being…

Patrice D. Cani
Professor Patrice D. Cani is researcher from the Belgian Fund for Scientific Research (FRS-FNRS), group leader in the Metabolism and Nutrition research group at the Louvain Drug Research Institute (LDRI) from the Université catholique de Louvain (UCL), Brussels, Belgium, and WELBIO (Walloon Excellence in Lifesciences and BIOtechnology) investigator. He is currently member of several international associations, he is member of the Alumni College from the Royal Belgian Academy of Sciences, and he has been elected in the board of directors of the LDRI (UCL). Patrice D. Cani has a M.Sc. in Nutrition and another M.Sc. in health Sciences, he is registered dietitian and PhD in Biomedical Sciences. His main research interests are the investigation of the role of the gut microbiota in the development of metabolic disorders, such as obesity, type 2 diabetes and low grade inflammation. More specifically, he is investigating the interactions between the gut microbiota, the host and specific biological systems such as the endocannabinoid system and the innate immune system in the context of obesity, type 2 diabetes and metabolic inflammation. Prof Cani is author and co-author of more than 110 scientific research papers published in peer-reviewed international journals, conferences and book chapters.

Using mice models, scientists from UCL and WUR found that Akkermansia muciniphila could have a role in reversing high-fat diet-induced metabolic disorders, in this study obesity and type-2 diabetes. The two first authors, Amandine Everard and Clara Belzer, having respectively a background in Pharmaceutical Sciences and Molecular Microbiology accepted to give us their feedback on their main findings.   1)…

GMFH Editing Team
GMFH Editing Team

Using mice models, scientists from UCL and WUR found that Akkermansia muciniphila could have a role in reversing high-fat diet-induced metabolic disorders, in this study obesity and type-2 diabetes. The two first authors, Amandine Everard and Clara Belzer, having respectively a background in Pharmaceutical Sciences and Molecular Microbiology accepted to give us their feedback on their main findings.   1)…

GMFH Editing Team
GMFH Editing Team

(This report can be downloaded for free as a PDF.) One of the most intimate relationships that our body has with the outside world is through our gut. Our gastrointestinal tracts harbor a vast and still largely unexplored microbial world known as the human microbiome that scientists are only just beginning to understand. Researchers are recognizing the integral role of…

GMFH Editing Team
GMFH Editing Team

(This report can be downloaded for free as a PDF.) One of the most intimate relationships that our body has with the outside world is through our gut. Our gastrointestinal tracts harbor a vast and still largely unexplored microbial world known as the human microbiome that scientists are only just beginning to understand. Researchers are recognizing the integral role of…

GMFH Editing Team
GMFH Editing Team

Speakers: Nicholas Talley (Australia), Annamaria Staiano (Italy), Marc Benninga (The Netherlands), Lukas van Oudenhove (Belgium)   “The definition of functional gastrointestinal disorders (FGIDs) as laid out in the Rome III criteria is now highly questionable.” This was the view expressed by Professor Nicholas Talley of the University of Newcastle, Australia when introducing his presentation on the Epidemiology of FGIDs and…

GMFH Editing Team
GMFH Editing Team

Speakers: Nicholas Talley (Australia), Annamaria Staiano (Italy), Marc Benninga (The Netherlands), Lukas van Oudenhove (Belgium)   “The definition of functional gastrointestinal disorders (FGIDs) as laid out in the Rome III criteria is now highly questionable.” This was the view expressed by Professor Nicholas Talley of the University of Newcastle, Australia when introducing his presentation on the Epidemiology of FGIDs and…

GMFH Editing Team
GMFH Editing Team